Chris Degnan Named New CFO at UroGen, Prepares for UGN-102 Launch
In an exciting development, Chris Degnan has been appointed as the new Chief Financial Officer at UroGen, taking over from Don Kim. The company expresses gratitude to Don for his past achievements and welcomes Chris with open arms as he brings his expertise to the table in preparing for the launch of UGN-102.
A Welcome Addition with a Wealth of Experience
Chris Degnan comes with a wealth of experience in the biotech industry, having served as CFO in companies like Galera Therapeutics and Verrica Pharmaceuticals. His extensive knowledge and proven track record make him a valuable asset to UroGen as they move forward with their new projects.
Inducement Grant for Mr. Degnan
Upon his appointment, Mr. Degnan will receive an inducement grant of stock units and stock options, showcasing the company's confidence in his ability to lead them to success in the upcoming ventures.
Looking Towards a Bright Future
With Chris Degnan at the helm as the CFO, UroGen is gearing up for an exciting period ahead. His leadership and expertise are sure to play a crucial role in the company's growth and success in the competitive biotech landscape.
In conclusion, the appointment of Chris Degnan as CFO marks a significant milestone for UroGen and sets the stage for future innovations and achievements. The company is poised to make great strides under his guidance, especially as they prepare to launch UGN-102 and tackle new challenges in the biotech industry.